Site icon pharmaceutical daily

Saama Redefines the Future of Clinical Development with Groundbreaking GenAI and Collaborative Platform Enhancements

CAMPBELL, Calif.–(BUSINESS WIRE)–Today, Saama announced the release of several groundbreaking features within its AI-driven platform, including generative AI (GenAI) chat and interactive review listings (IRL), creating an unparalleled, workflow-driven environment for cross-functional collaboration. For the first time, users can ask questions of their data in natural language, and instantly receive responses – eliminating costly data analysis delays. Additionally, data management and medical review teams can now work together in a single system to complete comprehensive data reviews from start to finish.


“Outdated approaches to clinical development are delaying treatments from making it to market, and ultimately patients,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama. “These cutting-edge features embedded within the Saama platform create a collaborative environment where AI can quickly surface insights and drive users to action. The result is the breakdown of operational silos and the acceleration of development timelines.”

Saama is fundamentally changing how drug development is done by integrating pioneering innovations into its award-winning platform. New features and enhancements now available include:

When using Saama’s innovative solutions, clinical trial sponsors and contract research organizations reduce the time from data capture to query generation by nearly one month and reduce the time to generate a single query by 90%.

“At Saama, we are committed to fostering innovation so that we may best support the complex needs of, and ultimately deliver value to, our customers,” said Avi Kulkarni, Chief Customer Success and Growth Officer. “The continued evolution of the Saama platform provides the foundational tools to modernize R&D and allow clinical development teams to do what they do best – gain insights from data to drive medical breakthroughs.”

By applying AI and advanced analytics to key clinical development processes, Saama’s platform eliminates manual, resource-intensive activities, allowing life science organizations to optimize productivity as well as gain deeper insights into patients’ behaviors and their real-time response to treatments.

To learn more about the Saama platform and its custom solutions and services, or to schedule a personalized demonstration, visit saama.com.

We also invite you to meet us at booth 132 at the SCOPE Summit from February 11-14 in Orlando, Florida.

About Saama

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

Contacts

Kate Mikus
Senior Director, Engagement Marketing

kate.mikus@saama.com

Heather Shea
Catalytic Agency on behalf of Saama

heather.shea@catalyticagency.com

Exit mobile version